HHS taps Medidata for data to inform research into drug development costs

Medidata ($MDSO) has contributed data to an assessment of factors that drive up the cost of drug development. The resulting paper, which was coauthored by staffers at the Department of Health and Human Services (HHS), found clinical procedure costs were the top cost driver, adding evidence to the argument that the rising complexity of protocols has pushed up study budgets. Medidata provided data from repositories associated with its CRO contract and grant management offerings to support the research. Release